152 related articles for article (PubMed ID: 32302984)
1. Expression of additional transcription factors is of prognostic value for aggressive behavior of pituitary adenomas.
Micko A; Rötzer T; Hoftberger R; Vila G; Oberndorfer J; Frischer JM; Knosp E; Wolfsberger S
J Neurosurg; 2020 Apr; 134(3):1139-1146. PubMed ID: 32302984
[TBL] [Abstract][Full Text] [Related]
2. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
3. Implications of MGMT methylation status in pituitary adenoma.
Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
[TBL] [Abstract][Full Text] [Related]
4. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification.
Ho DM; Hsu CY; Ting LT; Chiang H
Histopathology; 2001 Sep; 39(3):310-9. PubMed ID: 11532042
[TBL] [Abstract][Full Text] [Related]
5. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
[TBL] [Abstract][Full Text] [Related]
6. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
7. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
8. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
[TBL] [Abstract][Full Text] [Related]
9. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
10. [The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].
Jiang XB; Hu B; Fan X; He DS; Mao ZG; Chen M; Zhu YH; Wang HJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 May; 44(3):462-5. PubMed ID: 23898536
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
12. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification.
Micko AS; Wöhrer A; Wolfsberger S; Knosp E
J Neurosurg; 2015 Apr; 122(4):803-11. PubMed ID: 25658782
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas.
Aydin S; Comunoglu N; Ahmedov ML; Korkmaz OP; Oz B; Kadioglu P; Gazioglu N; Tanriover N
World Neurosurg; 2019 Oct; 130():e765-e774. PubMed ID: 31295602
[TBL] [Abstract][Full Text] [Related]
14. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
15. The 2017 WHO classification of pituitary adenoma: overview and comments.
Inoshita N; Nishioka H
Brain Tumor Pathol; 2018 Apr; 35(2):51-56. PubMed ID: 29687298
[TBL] [Abstract][Full Text] [Related]
16. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.
Mete O; Gomez-Hernandez K; Kucharczyk W; Ridout R; Zadeh G; Gentili F; Ezzat S; Asa SL
Mod Pathol; 2016 Feb; 29(2):131-42. PubMed ID: 26743473
[TBL] [Abstract][Full Text] [Related]
17. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
18. Expression of FOXL2 in human normal pituitaries and pituitary adenomas.
Egashira N; Takekoshi S; Takei M; Teramoto A; Osamura RY
Mod Pathol; 2011 Jun; 24(6):765-73. PubMed ID: 21478824
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
20. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
